Our NGS Oncology DxBook reveals many interesting trends in clinical oncology NGS.

‍

Most notably, the U.S. shows an unwavering preference for Illumina, with a surprising surge in WES activity in Academic Medical Centers (AMCs).

Europe, on the other hand, seems to be embracing Thermo Fisher, especially for smaller gene panels.

‍

Our insights reveal more than just tools of choice; they highlight the nuances in technical expertise, research inclination, and reimbursement structures across regions.

‍

Feel free to contact Michelle and Rishikesh to discuss more NGS trends! And swipe for more!

‍

‍